ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,003,462 | -32.9% | 144,120 | -22.9% | 0.00% | 0.0% |
| Q2 2023 | $4,477,621 | +32.7% | 186,957 | +4.3% | 0.00% | 0.0% |
| Q1 2023 | $3,373,053 | +109.7% | 179,227 | +77.4% | 0.00% | – |
| Q4 2022 | $1,608,509 | -4.8% | 101,037 | -2.1% | 0.00% | -100.0% |
| Q3 2022 | $1,689,000 | +15.5% | 103,201 | -0.6% | 0.00% | – |
| Q2 2022 | $1,462,000 | -63.5% | 103,786 | -37.3% | 0.00% | -100.0% |
| Q1 2022 | $4,010,000 | -16.0% | 165,543 | -19.0% | 0.00% | 0.0% |
| Q4 2021 | $4,773,000 | +46.5% | 204,458 | +4.2% | 0.00% | 0.0% |
| Q3 2021 | $3,259,000 | -15.6% | 196,187 | +23.9% | 0.00% | 0.0% |
| Q2 2021 | $3,862,000 | -28.6% | 158,391 | -24.5% | 0.00% | 0.0% |
| Q1 2021 | $5,412,000 | -42.8% | 209,803 | +18.5% | 0.00% | -50.0% |
| Q4 2020 | $9,466,000 | +13.9% | 177,047 | -12.1% | 0.00% | 0.0% |
| Q3 2020 | $8,314,000 | -21.2% | 201,528 | -7.5% | 0.00% | -33.3% |
| Q2 2020 | $10,557,000 | +8.6% | 217,801 | -5.3% | 0.00% | 0.0% |
| Q1 2020 | $9,720,000 | +8.0% | 230,061 | +9.3% | 0.00% | +50.0% |
| Q4 2019 | $9,001,000 | +21.0% | 210,395 | +1.8% | 0.00% | 0.0% |
| Q3 2019 | $7,441,000 | +39.8% | 206,749 | +3.8% | 0.00% | 0.0% |
| Q2 2019 | $5,324,000 | -0.4% | 199,165 | +0.0% | 0.00% | 0.0% |
| Q1 2019 | $5,347,000 | +69.3% | 199,135 | +2.0% | 0.00% | +100.0% |
| Q4 2018 | $3,158,000 | -17.3% | 195,269 | +6.1% | 0.00% | 0.0% |
| Q3 2018 | $3,819,000 | -10.5% | 184,004 | -34.1% | 0.00% | 0.0% |
| Q2 2018 | $4,265,000 | +2.9% | 279,317 | +51.4% | 0.00% | 0.0% |
| Q1 2018 | $4,145,000 | -6.7% | 184,464 | +25.0% | 0.00% | 0.0% |
| Q4 2017 | $4,442,000 | -31.8% | 147,513 | -14.6% | 0.00% | -50.0% |
| Q3 2017 | $6,509,000 | +33.1% | 172,810 | -1.5% | 0.00% | 0.0% |
| Q2 2017 | $4,890,000 | +4.7% | 175,368 | +29.1% | 0.00% | 0.0% |
| Q1 2017 | $4,672,000 | +28.3% | 135,888 | +7.6% | 0.00% | +100.0% |
| Q4 2016 | $3,642,000 | +92.5% | 126,280 | +112.2% | 0.00% | 0.0% |
| Q3 2016 | $1,892,000 | -2.2% | 59,508 | -0.1% | 0.00% | 0.0% |
| Q2 2016 | $1,934,000 | -11.9% | 59,584 | -24.1% | 0.00% | 0.0% |
| Q1 2016 | $2,194,000 | -17.3% | 78,477 | +5.4% | 0.00% | 0.0% |
| Q4 2015 | $2,654,000 | +6.0% | 74,422 | -1.7% | 0.00% | 0.0% |
| Q3 2015 | $2,504,000 | +18.5% | 75,740 | +50.2% | 0.00% | 0.0% |
| Q2 2015 | $2,113,000 | -1.7% | 50,434 | -23.6% | 0.00% | – |
| Q1 2015 | $2,150,000 | +16.6% | 65,976 | +13.6% | 0.00% | -100.0% |
| Q4 2014 | $1,844,000 | +27.1% | 58,082 | -0.9% | 0.00% | 0.0% |
| Q3 2014 | $1,451,000 | -13.5% | 58,586 | -21.1% | 0.00% | 0.0% |
| Q2 2014 | $1,678,000 | +1.8% | 74,268 | +9.6% | 0.00% | 0.0% |
| Q1 2014 | $1,648,000 | +2.3% | 67,766 | +5.1% | 0.00% | 0.0% |
| Q4 2013 | $1,611,000 | +157.3% | 64,479 | +183.1% | 0.00% | – |
| Q3 2013 | $626,000 | +154.5% | 22,776 | +68.2% | 0.00% | – |
| Q2 2013 | $246,000 | – | 13,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |